首页> 外文期刊>The Journal of Steroid Biochemistry and Molecular Biology >A role for the cell cycle phosphatase Cdc25a in vitamin D-dependent inhibition of adult rat vascular smooth muscle cell proliferation.
【24h】

A role for the cell cycle phosphatase Cdc25a in vitamin D-dependent inhibition of adult rat vascular smooth muscle cell proliferation.

机译:细胞周期磷酸酶Cdc25a在维生素D依赖性抑制成年大鼠血管平滑肌细胞增殖中的作用。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

We have explored the mechanism(s) underlying 1,25 dihydroxyvitamin D's (1,25(OH)(2)D) suppression of agonist-induced vascular smooth muscle cell (VSMC) proliferation. Quiescent cultured adult rat VSMC were treated with 1,25(OH)(2)D for 48h and endothelin (ET) or angiotensin II (AII) for the final 24h. We show that VSMC responded to 1,25(OH)(2)D or its less hypercalcemic analogue RO 25-6760 with approximately 70% inhibition of ET-dependent (3)H-thymidine incorporation. The inhibition was linked to a comparable reduction in ET-stimulated cyclin-dependent kinase 2 (Cdk2) activity and suppression of an ET-induced Cdk2 activator, cell division cycle 25 homolog A (Cdc25A). Both 1,25(OH)(2)D and RO 25-6760 completely inhibited the ET-dependent increase in Cdc25A mRNA and protein levels, phosphatase and promoter activities. 1,25(OH)(2)D also suppressed AII-induced DNA synthesis, Cdk2 activity and Cdc25A gene transcription. Inhibition of Cdc25A gene expression using a siRNA approach resulted in significant inhibition of ET or AII-dependent Cdk2 activity and (3)H-thymidine incorporation. The Cdc25A siRNA-mediated inhibition of ET or AII-induced Cdk2 activity and DNA synthesis was not additive with that produced by 1,25(OH)(2)D treatment. These data demonstrate that 1,25(OH)(2)D inhibits VSMC proliferation through a Cdc25A-dependent mechanism and suggest that this hormone may prove useful in the management of disorders characterized by aberrant proliferation of VSMC in the vascular wall.
机译:我们探索了抑制激动剂诱导的血管平滑肌细胞(VSMC)增殖的1,25二羟基维生素D(1,25(OH)(2)D)的潜在机制。静息培养的成年大鼠VSMC用1,25(OH)(2)D处理48h,最后24h用内皮素(ET)或血管紧张素II(AII)处理。我们显示VSMC响应1,25(OH)(2)D或其较少的高钙类似物RO 25-6760,对ET依赖性(3)H-胸苷掺入的抑制约为70%。抑制作用与ET刺激的细胞周期蛋白依赖性激酶2(Cdk2)活性的降低和ET诱导的Cdk2激活剂(细胞分裂周期25同源物A(Cdc25A))的抑制有关。 1,25(OH)(2)D和RO 25-6760都完全抑制了ET依赖性Cdc25A mRNA和蛋白水平,磷酸酶和启动子活性的增加。 1,25(OH)(2)D还抑制了AII诱导的DNA合成,Cdk2活性和Cdc25A基因转录。使用siRNA方法抑制Cdc25A基因表达导致对ET或AII依赖性Cdk2活性和(3)H-胸苷掺入的显着抑制。 Cdc25A siRNA介导的对ET或AII诱导的Cdk2活性和DNA合成的抑制作用与1,25(OH)(2)D处理产生的抑制作用无关。这些数据表明,1,25(OH)(2)D通过Cdc25A依赖性机制抑制VSMC增殖,并表明该激素可用于治疗以VSMC在血管壁异常增殖为特征的疾病。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号